Lawrence Otto Klein Sells 75,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Otto Klein sold 75,000 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the sale, the chief executive officer owned 925,580 shares of the company’s stock, valued at approximately $84,996,011.40. This trade represents a 7.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lawrence Otto Klein also recently made the following trade(s):

• On Monday, June 15th, Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total value of $120,494.01.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $91.63 on Thursday. Oruka Therapeutics, Inc. has a fifty-two week low of $14.66 and a fifty-two week high of $115.51. The firm has a market capitalization of $6.07 billion, a price-to-earnings ratio of -45.14 and a beta of -0.34. The stock’s 50-day simple moving average is $95.11 and its 200-day simple moving average is $69.01.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wedbush reiterated an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. BTIG Research restated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Finally, Guggenheim reiterated a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $134.30.

Institutional Trading of Oruka Therapeutics

Large investors have recently made changes to their positions in the business. Legal & General Group Plc acquired a new position in Oruka Therapeutics during the second quarter valued at $28,000. Nykredit A S acquired a new stake in Oruka Therapeutics during the 2nd quarter worth about $29,000. BNP Paribas Financial Markets grew its position in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares during the period. Royal Bank of Canada raised its stake in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the 4th quarter valued at about $37,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.